90 patents
Utility
Synthesis of Tetrahydronaphthalenols and Uses Thereof
28 Dec 23
Provided herein are compounds and synthetic methods useful for preparing tetrahydronaphthalenol derivatives, and uses of the compounds prepared.
Vidyasagar Vuligonda
Filed: 27 Jun 23
Utility
Autoimmune disorder treatment using RXR agonists
24 Oct 23
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 27 Jan 22
Utility
Methods of using RARĪ³ agonists for cancer treatment
24 Oct 23
The invention discloses novel RAR gamma selective agonists used in the treatment of cancer.
Martin E. Sanders, Vidyasagar Vuligonda
Filed: 23 Nov 22
Utility
RAR selective agonists in combination with immune modulators for cancer immunotherapy
17 Oct 23
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 16 Dec 20
Utility
Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
10 Oct 23
Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 16 Dec 20
Utility
Use of CYP26-RESISTANT Rar Alpha Selective Agonists In the Treatment of Cancer
5 Oct 23
Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RARα) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
Filed: 28 Apr 23
Utility
Treatment of Autoimmune Diseases with Combinations of RXR Agonists and Thyroid Hormones
21 Sep 23
The present specification provides methods of treating a transplant rejection, pulmonary fibrosis, or glomerulonephritis with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 19 May 23
Utility
RXR Agonist Salt Form, Polymorphs Thereof, and Uses Thereof
21 Sep 23
Provided herein are salt and solid forms of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, including a Tris salt form of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, and polymorphs thereof, methods of preparing the compounds, and their uses.
Vidyasagar Vuligonda, Martin E. Sanders, Shanming Kuang, Harsh Shailesh Shah
Filed: 14 Mar 23
Utility
Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
4 Jul 23
The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 15 Jan 21
Utility
Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
4 Jul 23
The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 26 Jan 22
Utility
Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
16 May 23
Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RARα) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
Filed: 29 Dec 20
Utility
Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
16 May 23
Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 3 Mar 22
Utility
Treatment of Disease with Esters of Selective RXR Agonists
27 Apr 23
The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 2 Nov 22
Utility
Treatment of Disease with Esters of Selective RXR Agonists
27 Apr 23
The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 2 Nov 22
Utility
METHODS OF USING RARy AGONISTS FOR CANCER TREATMENT
30 Mar 23
The invention discloses novel RAR gamma selective agonists used in the treatment of cancer.
Martin E. Sanders, Vidyasagar Vuligonda
Filed: 23 Nov 22
Utility
Autoimmune disorder treatment using RXR agonists
14 Feb 23
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 22 Dec 21
Utility
Autoimmune disorder treatment using RXR agonists
10 Jan 23
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 14 Jan 20
Utility
Treatment of disease with esters of selective RXR agonists
6 Dec 22
The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 20 Sep 18
Utility
Treatment of Diseases by Concurrently Eliciting Remyelination Effects and Immunomodulatory Effects Using Selective RXR Agonists
24 Nov 22
The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle, Martin E. Sanders
Filed: 7 Jul 22
Utility
Receptor Subtype and Function Selective Retinoid and Rexinoid Compounds In Combination with Immune Modulators for Cancer Immunotherapy
16 Jun 22
Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 3 Mar 22